India appeals for generic risdiplam access for spinal muscular atrophy patients
Patients with spinal muscular atrophy have written to the Indian prime minister seeking inclusion of the locally manufactured generic drug risdiplam in the rare disease policy. They stress that timely access is critical to prevent irreversible deterioration. The appeal is reported by The Hindu.
Advertisement: Article Inline